特拉唑嗪与托特罗定联合治疗良性前列腺增生的疗效评估

目的评价特拉唑嗪与托特罗定联合应用治疗良性前列腺增生的疗效。方法选择未经治疗的无严重梗阻症状的良性前列腺增生患者74例,随机分为特拉唑嗪组(单独使用特拉唑嗪,n=31)和联合用药组(特拉唑嗪+托特罗定,n=43),两组分别在治疗前后测定国际前列腺症状评分、储尿期刺激症状评分、最大尿流率、24 h平均尿量、残余尿量、24 h排尿次数、24 h尿失禁次数和夜尿次数,并记录出现的不良事件。结果用药12周后,特拉唑嗪组国际前列腺症状评分、储尿期刺激症状评分、残余尿量、24 h排尿次数、尿失禁次数及夜尿均次较治疗前均明显下降(P<0.05);最大尿流率和平均尿量较治疗前均明显上升(P<0.05);治疗后,联合用药组国际前列腺症状评分、储尿期刺激症状评分、尿失禁次数和夜尿次数与特拉唑嗪组相比均有明显改善,差异有统计学意义(P<0.05)。结论特拉唑嗪与托特罗定联合应用于无严重梗阻症状的良性前列腺增生患者,可以更全面地缓解症状,改善患者的生活质量。

Effectiveness of combined therapy with terazosin and tolterodine for patients with benign prostatic hyperplasia

Objective To evaluate the effectiveness of combined therapy with terazosin and tolterodine for patients with benign prostatic hyperplasia.Methods Seventy-four patients with benign prostatic hyperplasia without serious obstructive symptom were randomly assigned to terazosin group(treated with terazosin only,n=31) and combined therapy group(treated with terazosin and tolterodine,n=43).The International Prostate Symptoms Score(IPSS),score on the urinary storage phase symptoms,maximum urinary flow rate,mean voi...